Seeking Alpha
View as an RSS Feed

DWD Investing  

View DWD Investing's Comments BY TICKER:

Latest  |  Highest rated
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    Walsh,

    Where did I say it was "always the case." Comprehension is your friend.
    Jul 4, 2015. 04:30 PM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    "These authors are just regular investors like you and me."

    Wrong. Wildly wrong. :)
    Jul 4, 2015. 04:28 PM | Likes Like |Link to Comment
  • Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug? [View article]
    " I think its because stem cell companies have not done so hot recently."

    Well, same for gene trials, but they get billions in funding.

    OCATA has positive results using eHSC stem cells, a perfect safety record after Phase I for over 4 years. But their cells are not adult. Adult stem cells have failed miserably. They cannot get funded.
    Jul 4, 2015. 04:28 PM | 1 Like Like |Link to Comment
  • Premarket Gainers / Losers as of 9:10 am [View news story]
    NAVB? Sure they do, it's already commercialized and making money. It's called Lymphoseek. Check the website.
    Jul 3, 2015. 07:20 PM | Likes Like |Link to Comment
  • Navidea Biopharmaceuticals' (NAVB) CEO Rick Gonzalez on Q1 2015 Results - Earnings Call Transcript [View article]
    The only red flag is hit pieces by desperate shorts. "Oneotherfool" and I am working on a NAVB article currently showing how it has massive upside from LS alone--without Manocept Targeted Oncology. Should be out some time next week, I assume. It just depends on how fast we can put it together.We've both been doing lots of research on possible revenues, etc., for months now. Best our numbers can do with support is in the near 100M range for EU and USA in 2017. Half that approximately for US only. That puts the SP at $4.5+ roughly, just in the US, without EU coming on line.
    Jul 3, 2015. 07:19 PM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    A good rule of thumb is that in biotech, "Phase I" = "Failed."

    Phase I is a necessary condition of any biotech, but finding one with a commercialized product, in addition to Phase I pipelines, and cash positive (whether funded or revenue) is a big benefit in success.
    Jul 3, 2015. 07:14 PM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    Walsh,

    That is incorrect. Professional investors working for corporations write articles for SA also, see "Trefis" (Team from MIT) for example, Jeff Miller, and Bret Jensen, also. That was a wildly inaccurate comment you made.
    Jul 3, 2015. 07:12 PM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    ty-much appreciated.

    Looks likely have actually 4 either in trial or in Phase III commercial stage.
    Jul 3, 2015. 07:05 PM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    Catch--Makes perfect sense because if they need that money,they can lower the warrant strike and if holders exercise their warrants, they will receive cash for them.

    Thanks.
    Jul 3, 2015. 07:05 PM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    Brook,

    Big money has access to all of the information we don't have. They aren't taking positions in the open market, rather, they a reinvesting in OCAT. So they can use inside information to do that, just like a bank can when lending money. Look, 'big money' knows EXACTLY what the results are and what they mean, and the fact they can't get funded, well, that's what makes me nervous--they have that information, yet, no funding, sorry.

    I just think they don't want to touch stem cells, even if a company can regrow a limb from an amputee. Nope, sorry!
    Jul 3, 2015. 07:02 PM | Likes Like |Link to Comment
  • Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug? [View article]
    Gene therapy is adopted by big pharma funding because it is elegant and easy to commercialize, yet gene therapy is more complicated than Stem Cells, the way I understand it, because Genes are connected and interconnected and we still don't understand all of the connections. Embryonic derived Stem Cells can do anything we tell them to do, and nothing else, which we do understand. Yet problems in commercializing stem cells is problematic enough to fear off big institutions funding stem cell companies, even using virtually proven therapies using derived or grown embryonic stem cells (no embryo damaged).

    Sad, but from what information I've read, true. And big pharma will probably keep pumping billions into failing gene therapies before even considering stem cell therapies that have current better end point data in clinical trials, vastly superior, in fact.

    On the upside, future looking, decades probably, if it is possible to cure a disease using gene therapy, companies like AAVL will eventually succeed.
    Jul 3, 2015. 06:53 PM | 1 Like Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    Thanks for that update. Can I bother you for links?
    Jul 2, 2015. 02:14 PM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    It's just re-ranged between 5-5.30 like it was before, except at 6-6.3. That's why I'm looking for an exit on any mysterious pop, like when we got that 7.20 pop a while ago. I'll exit on 6.30 all day. Then watch it sink back to low 5s again. I might buy again and trade it, but I don't see any upside in a medium term. (Barring surprises based on hope.)

    That and the longer it goes without guidance from management and continuing delays starting Phase II, the less upside I see in the longer term also.
    Jul 2, 2015. 01:58 PM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    For whatever reason, and there are many, institutional investors are not keen to invest because of problems related to stem cell commercialization. Gene therapy is much easier, much more elegant, but so far, lacking in efficacy.
    Jul 2, 2015. 01:38 PM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    The comments section do not belong to the author, or anyone. So, yes, you're wrong.
    Jul 2, 2015. 01:36 PM | Likes Like |Link to Comment
COMMENTS STATS
10,202 Comments
6,421 Likes